

The Structure and Function of Surface Protein A in Bacterial Pathogenesis

**¹Sumana Majumder, Avinanda Kundu, ¹Priyajit Banerjee,
¹Debanshu Sharma ^{*2}Suranjana Sarkar**

¹Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal – 700121, India

¹Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal – 700121

Corresponding author at: Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121. Corresponding E-mail: suranjanas@svu.ac.in

ABSTRACT

Surface Protein A (SPA) is a key surface-associated protein found in various pathogenic bacteria, including *Streptococcus pneumoniae*. SPA plays a critical role in the interaction between bacteria and host cells, facilitating adhesion, immune evasion, and biofilm formation, all of which contribute to bacterial virulence. Structurally, SPA proteins are characterized by their ability to bind to host immune components, such as immunoglobulins and complement proteins, which enable the bacteria to avoid immune detection and clearance. The protein's structure typically includes a series of repeating domains that are crucial for its interaction with host receptors. Additionally, SPA proteins are involved in bacterial aggregation and the formation of biofilms, providing the bacteria with a protective niche against environmental stressors, including antimicrobial agents and immune responses. This abstract reviews the structural features of SPA proteins and their functional implications in bacterial pathogenesis, highlighting their potential as therapeutic targets for the development of vaccines and novel antimicrobial strategies. Understanding the structure-

function relationship of SPA proteins is essential for designing interventions aimed at disrupting bacterial adherence and immune evasion, thereby mitigating infections caused by these pathogens.

Keywords: Adhesion, Biofilm, Immune Evasion, Surface Protein A, Virulence

Introduction


Staphylococcus aureus is a major bacterial pathogen responsible for various infections, ranging from minor skin ailments to severe systemic diseases. One of its key virulence factors is Staphylococcal Protein A (SpA), (PDB ID:1SE2) a surface protein that plays a crucial role in bacterial survival by evading host immune responses. SpA binds to immunoglobulins, disrupts phagocytosis, induces inflammatory pathways, and contributes to biofilm formation, making it an essential component of *S. aureus* pathogenesis. This review explores the structure of SpA, its role in immune evasion, its contributions to different infections, and its potential as a target for novel therapeutic interventions. Additionally, it discusses SpA's evolutionary significance and challenges associated with targeting it for clinical applications. *Staphylococcus aureus* is a highly adaptable bacterial species capable of existing as a commensal organism on the human body while also acting as a significant pathogen. It is responsible for a wide range of infections, including skin infections, pneumonia, osteomyelitis, endocarditis, and sepsis. One of the primary reasons for its ability to cause such diverse infections is its extensive virulence factor repertoire, which includes toxins, adhesins, and immune-modulating proteins (Votintseva et al., 2011; O'Halloran et al., 2015).

Among these virulence factors, Staphylococcal Protein A (SpA) is one of the most crucial. SpA enables *S. aureus* to evade the host immune system, allowing it to survive and persist in infected tissues. This protein is involved in various mechanisms, including immune system interference, inflammation induction, and biofilm development. Given its central role in bacterial pathogenesis, SpA is an attractive

target for therapeutic interventions aimed at reducing the severity of *S. aureus* infections.

Structural Features of Protein A

SpA is a **cell-wall-anchored protein** that is covalently attached to *S. aureus* via a specific sorting mechanism. It consists of **five immunoglobulin-binding domains**, labeled **E, D, A, B, and C**, which allow it to interact with host immune components. These domains are made up of **three-helix bundles**, a structural formation that enables strong binding to host proteins.



At the C-terminal region, SpA has a sorting signal that facilitates its attachment to the bacterial peptidoglycan layer. This ensures that SpA remains on the bacterial surface, where it can interact with host immune cells. However, *S. aureus* is also capable of releasing SpA into the extracellular environment, where it retains its immunomodulatory properties and affects immune responses even at a distance from bacterial cells.

Structural Features of Protein A

Domain Organization

Protein A (*SpA*) is composed of distinct structural components that contribute to its function in immune evasion (Swaminathan et al., 1995; Graille et al., 2000):

- **Immunoglobulin-binding domains:** It contains five homologous domains—E, D, A, B, and C—each approximately **58 amino acids in length**. These domains allow SpA to interact with host antibodies.
- **C-terminal sorting signal:** This region enables SpA to attach to the bacterial **peptidoglycan layer** with the help of **sortase enzymes**, securing it to the bacterial cell wall.
- **Flexible linker region:** This section provides structural adaptability, allowing **SpA to undergo conformational changes** when interacting with immune molecules.

Each of the **immunoglobulin-binding domains** is arranged in a **three-helix bundle** structure, a configuration essential for its ability to attach to host immune proteins.

Active Center and Key Amino Acids

The **active site** of Protein A is found within its immunoglobulin-binding domains and is composed of specific **amino acid residues** that contribute to its function:

- **Tyrosine (Tyr):** Plays a key role in **hydrophobic interactions** with the Fc region of **IgG antibodies**, enabling SpA to bind immunoglobulins and prevent immune recognition.
- **Leucine (Leu) and Phenylalanine (Phe):** Help **maintain the structural integrity** of the binding domains and contribute to **high-affinity interactions** with host immunoglobulins.
- **Glutamic acid (Glu) and Aspartic acid (Asp):** Involved in **electrostatic interactions** with host proteins, enhancing the stability of **SpA-host interactions**.
- **Lysine (Lys):** Crucial for **binding specificity**, particularly in interactions with **B cell receptors** and **tumor necrosis factor receptor-1 (TNFR-1)**, influencing immune modulation and inflammatory

responses.

The combination of **hydrophobic** and **charged amino acids** in these domains allows **SpA to effectively engage with immune system components**, thereby **interfering with immune signaling pathways** and promoting bacterial survival.

Immune Evasion Mechanisms of Protein A

1. Binding to Immunoglobulins

SpA has a unique ability to bind the Fc region of IgG antibodies, preventing opsonization and subsequent recognition by phagocytes. Opsonization is a key immune mechanism in which antibodies mark pathogens for destruction by immune cells such as neutrophils and macrophages. By interfering with this process, SpA allows *S. aureus* to remain undetected and persist in host tissues.

2. Disruption of B Cell Function

In addition to binding IgG, SpA can also interact with the Fab region of VH3 family B cell receptors, leading to non-specific B cell activation. This interaction ultimately results in B cell apoptosis, weakening the host's adaptive immune response and reducing its ability to generate effective antibodies against the infection. This mechanism provides *S. aureus* with an advantage by limiting the host's capacity to mount a long-term immune defense.

3. Activation of Inflammatory Pathways

SpA is capable of binding tumor necrosis factor receptor-1 (TNFR-1) on epithelial and immune cells. This interaction stimulates the production of pro-inflammatory cytokines, leading to excessive inflammation. While inflammation is an essential component of the immune response, uncontrolled inflammation can damage host tissues and facilitate bacterial survival. This mechanism is particularly relevant in conditions such as staphylococcal pneumonia, where SpA-induced inflammation exacerbates disease severity.

Role of Protein A in Various Infections

The role of SpA in diverse infections are mentioned below (Becker et al., 2014; Bear et al., 2023)

1. Skin and Soft Tissue Infections

SpA contributes to abscess formation, cellulitis, and impetigo by impairing phagocytosis and enhancing bacterial adherence to host tissues. It also aids in immune evasion, allowing *S. aureus* to persist in the skin and subcutaneous tissues.

2. Bloodstream Infections and Sepsis

In bacteremia and sepsis, SpA prevents immune clearance by interfering with opsonization and phagocytosis. Additionally, by stimulating TNFR-1, SpA promotes systemic inflammation, contributing to septic shock and organ dysfunction.

3. Respiratory Infections

SpA plays a key role in staphylococcal pneumonia by triggering excessive inflammation in lung tissues. This results in tissue damage and fluid accumulation, worsening respiratory distress in affected individuals.

4. Bone and Joint Infections

In osteomyelitis and septic arthritis, SpA promotes **bacterial attachment to osteoblasts** and contributes to **biofilm formation on bone surfaces**. These biofilms make infections harder to treat, leading to **chronic infections and increased antibiotic resistance**.

Evolutionary Significance of Protein A

SpA's widespread presence in **clinical isolates of *S. aureus*** suggests that it provides a strong **evolutionary advantage** for bacterial survival. The ability to bind immunoglobulins and modulate host immunity has likely contributed to *S. aureus* becoming one of the most successful **opportunistic pathogens** in human history.

Therapeutic Approaches Targeting Protein A

The therapeutic approach of SpA is mentioned below (Fox et al., 2021):

1. Vaccine Development

Because of its central role in immune evasion, SpA has been explored as a **vaccine target**. Some experimental vaccines aim to **generate antibodies that neutralize SpA**, preventing it from interfering with the immune response and allowing the body to effectively clear *S. aureus* infections.

2. Monoclonal Antibodies

Therapeutic **monoclonal antibodies** against SpA have been developed to **block its interaction with IgG**. By doing so, these antibodies restore **normal immune functions**, helping the host fight off infections more efficiently.

3. Small Molecule Inhibitors

Another promising approach involves **small molecule inhibitors** that disrupt SpA's ability to bind **immunoglobulins and TNFR-1**. These inhibitors could potentially **reduce bacterial virulence** and improve the effectiveness of conventional antibiotics.

Challenges in Targeting Protein A

Despite its potential as a therapeutic target, SpA presents several challenges:

- **Genetic variability:** Different *S. aureus* strains may have variations in SpA, affecting vaccine efficacy.
- **Functional redundancy:** *S. aureus* possesses multiple immune evasion strategies, meaning SpA inhibition alone may not completely neutralize its virulence.
- **Host interactions:** Because SpA interacts with **host proteins**, there is a risk of unintended immune system effects when targeting it therapeutically.

Conclusion

Staphylococcal Protein A is a key virulence factor that enhances *S. aureus* immune evasion, promotes persistent infections, and contributes to disease progression. Its diverse mechanisms of phagocytosis inhibition, B cell manipulation, and inflammation induction make it a major player in bacterial

pathogenesis. Given its crucial role, therapeutic interventions targeting SpA, including vaccines, monoclonal antibodies, and small molecule inhibitors, hold significant potential for treating *S. aureus* infections. However, further research is needed to overcome challenges related to bacterial resistance and immune system interactions.

Reference

Bear, A., Locke, T., Rowland-Jones, S., Pecetta, S., Bagnoli, F., & Darton, T. C. (2023). The immune evasion roles of *Staphylococcus aureus* protein A and impact on vaccine development. *Frontiers in cellular and infection microbiology*, 13, 1242702.

Becker, S., Frankel, M. B., Schneewind, O., & Missiakas, D. (2014). Release of protein A from the cell wall of *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences of the United States of America*, 111(4), 1574–1579.

Fox, P. G., Schiavetti, F., Rappuoli, R., McLoughlin, R. M., & Bagnoli, F. (2021). Staphylococcal Protein A Induces Leukocyte Necrosis by Complexing with Human Immunoglobulins. *mBio*, 12(3), e0089921.

Graille, M., Stura, E. A., Corper, A. L., Sutton, B. J., Taussig, M. J., Charbonnier, J. B., & Silverman, G. J. (2000). Crystal structure of a *Staphylococcus aureus* protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. *Proceedings of the National Academy of Sciences of the United States of America*, 97(10), 5399–5404.

O'Halloran, D. P., Wynne, K., & Geoghegan, J. A. (2015). Protein A is released into the *Staphylococcus aureus* culture supernatant with an unprocessed sorting signal. *Infection and immunity*, 83(4), 1598–1609.

Swaminathan, S., Furey, W., Pletcher, J., & Sax, M. (1995). Residues defining V beta specificity in staphylococcal enterotoxins. *Nature structural biology*, 2(8), 680–686. 680

Votintseva, A. A., Fung, R., Miller, R. R., Knox, K., Godwin, H., Wyllie, D. H., Bowden, R., Crook, D. W., & Walker, A. S. (2014). Prevalence of *Staphylococcus aureus* protein A (spa) mutants in the community and hospitals in Oxfordshire. *BMC microbiology*, 14, 63.